Jonathan Polikoff

Kaiser Permanente San Diego Medical Center — United States

Medicine · Health Sciences

31h-index13.7kcitations84works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(26), Lymphoma Diagnosis and Treatment(16), Breast Cancer Treatment Studies(15), HER2/EGFR in Cancer Research(15), Chronic Lymphocytic Leukemia Research(14)

Publications83 total

Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Breast Cancer Research and Treatment·2022· 1 citedOpen Access
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)
Breast Cancer Research and Treatment·2022· 9 citedOpen Access
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer
Breast Cancer Research and Treatment·2022· 2 citedOpen Access
Definitive Results of a Phase III Adjuvant Trial Comparing Six Cycles of FEC-100 to Four Cycles of AC in Women with Operable Node-negative Breast Cancer: The NSABP B-36 Trial (NRG Oncology)
Research Square (Research Square)·2021· 3 citedOpen Access
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
Annals of Oncology·2021· 119 citedOpen Access
Phase II trial of bevacizumab and temozolomide for treatment of elderly patients with newly diagnosed glioblastoma.
Journal of Clinical Oncology·2020· 2 cited
NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
Journal of Clinical Oncology·2019· 406 citedOpen Access
Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)
Annals of Oncology·2019· 13 citedOpen Access
Alpelisib (ALP) + endocrine therapy (ET) by last prior therapy in patients (pts) with PIK3CA-mutated hormone-receptor positive (HR+) human epidermal growth factor receptor-2-Negative (HER2–) advanced breast cancer (ABC): Additional study cohort in BYLieve
Annals of Oncology·2019
Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)
Cancer Research·2018· 50 cited
Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2
Journal of Clinical Oncology·2017· 68 citedOpen Access
Abstract CT060: STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions
Cancer Research·2017· 18 cited
Phase II trial of bevacizumab and temozolomide for upfront treatment of elderly patients with newly diagnosed glioblastoma.
Journal of Clinical Oncology·2017· 1 cited
Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC
Pneumologie·2017· 1 cited
Detecting <i>NTRK</i>, <i>ROS1,</i> and <i>ALK</i> gene fusions in gastrointestinal tumor patients.
Journal of Clinical Oncology·2017· 4 cited
PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses
Journal of Thoracic Oncology·2017· 20 citedOpen Access
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
The Lancet·2016· 4.7k citedOpen Access
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Journal of Clinical Oncology·2016· 743 citedOpen Access
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
Annals of Oncology·2016· 70 citedOpen Access
Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer
Annals of Oncology·2016· 1 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Norman Wolmark(16), Charles E. Geyer(13), Louis Fehrenbacher(13), Eleftherios P. Mamounas(13), Priya Rastogi(11), Sandra M. Swain(11), James N. Atkins(10), Adam Brufsky(8), Joseph P. Costantino(8), Thomas E. Witzig(8), Craig B. Reeder(8), Julie M. Vose(7), Pier Luigi Zinzani(7), Dennis Pietronigro(7), Louise Provencher(6), André Robidoux(6), John L. Zapas(5), David D. Biggs(5), Soonmyung Paik(5), Rena Buckstein(5)